Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 4.9% – Here’s Why

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was down 4.9% on Tuesday . The company traded as low as $30.80 and last traded at $30.73. Approximately 103,624 shares traded hands during trading, a decline of 85% from the average daily volume of 682,991 shares. The stock had previously closed at $32.31.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on AGIO shares. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. Royal Bank of Canada lifted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, Scotiabank lifted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Price Performance

The company has a market capitalization of $1.77 billion, a P/E ratio of 2.72 and a beta of 0.90. The company has a 50 day moving average of $33.23 and a 200-day moving average of $41.04.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently made changes to their positions in AGIO. Erste Asset Management GmbH purchased a new position in Agios Pharmaceuticals during the third quarter valued at $97,199,000. Jefferies Financial Group Inc. bought a new position in shares of Agios Pharmaceuticals in the 4th quarter worth about $49,290,000. Vestal Point Capital LP purchased a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $33,767,000. Adage Capital Partners GP L.L.C. bought a new stake in Agios Pharmaceuticals during the fourth quarter worth about $9,957,000. Finally, Paradigm Biocapital Advisors LP purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth about $9,084,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.